Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Novartis-India-Limited"

4 News Found

Novartis India posts Q1 FY26 net profit at Rs. 27.62 Cr
News | July 30, 2025

Novartis India posts Q1 FY26 net profit at Rs. 27.62 Cr

Novartis India has reported total income of Rs. 98.16 crores during the period ended June 30, 2025

Novartis India posts Q4 FY24 net profit lower at Rs. 14.68 Cr
News | May 12, 2024

Novartis India posts Q4 FY24 net profit lower at Rs. 14.68 Cr

Novartis India has reported total income of Rs. 91.59 crores during the period ended March 31, 2024

Novartis India posts Q3 FY24 PAT at Rs. 26.57 Cr
News | January 28, 2024

Novartis India posts Q3 FY24 PAT at Rs. 26.57 Cr

Novartis India has reported total income of Rs. 106.50 crores during the period ended December 31, 2023

Novartis India Q1FY23 PAT jumps to Rs. 52.38 Cr
News | July 28, 2022

Novartis India Q1FY23 PAT jumps to Rs. 52.38 Cr

Novartis India has reported total income of Rs. 147.44 crores during the period ended June 30, 2022.

Latest Stories

Fermenta receives CEP by EDQM for Vitadee 100 SD

Zydus completes acquisition of 85.6% stake in Amplitude Surgical

Bliss GVS Pharma posts Q1 FY26 PAT higher at Rs. 43.03 Cr

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging